OPTION AND LICENSE AGREEMENTOption and License Agreement • October 20th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 20th, 2017 Company Industry JurisdictionTHIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made effective as of February 27, 2017 (the “Effective Date”), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (“Arsanis”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • September 20th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 20th, 2017 Company Industry JurisdictionTHIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made effective as of February 27, 2017 (the “Effective Date”), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (“Arsanis”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 10th, 2017 Company Industry JurisdictionTHIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made effective as of February 27, 2017 (the “Effective Date”), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (“Arsanis”).